Vedang Murthy1, Shwetabh Sinha2, Sadhana Kannan3, Debanjali Datta2, Rabi Das2, Ganesh Bakshi4, Gagan Prakash4, Rahul Krishnatry2. 1. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India. Electronic address: vmurthy@actrec.gov.in. 2. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India. 3. Department of Biostatistics, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Kharghar, Navi Mumbai, India. 4. Division of Urology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India.
Abstract
PURPOSE: To determine the genitourinary (GU) toxicity outcomes in prostate cancer patients treated with stereotactic body radiation therapy (SBRT) who have undergone a prior transurethral resection of prostate (TURP) and compare it to a similar non-TURP cohort. MATERIALS AND METHODS: Fifty prostate cancer patients who had undergone a single TURP, had a good baseline urinary function, and had been subsequently treated with SBRT were chosen from a prospectively maintained database. These were propensity score matched to a similar non-TURP cohort treated during the same period. Matching was done for diabetes mellitus and volume of radiation therapy. Acute GU and late GU toxicity were scored using the Radiation Therapy Oncology Group (RTOG) criteria. Stricture and incontinence were scored using Common Terminology for Common Adverse Events version 4.0. RESULTS: Median follow-up for the entire cohort was 26 months (non-TURP vs TURP, 30 months vs 22 months, P = .34). The median duration between TURP and start of SBRT was 10 months. There was no significant difference between non-TURP versus TURP cohort in terms of RTOG acute GU toxicities grade ≥2 (8% vs 6%, P = .45), RTOG late GU toxicities grade ≥2 (8% vs 12%, P = .10), stricture rates (4% vs 6%, P = .64), and incontinence rates (0% vs 4%, P = .15). The median duration of time to late toxicity was 16 months vs 10 months (P = .12) in non-TURP and TURP cohort, respectively. CONCLUSIONS: Although modestly increased as compared with non-TURP patients, GU toxicities remains low with SBRT in post-TURP patients. SBRT can be safely performed in carefully selected post-TURP prostate cancer patients.
PURPOSE: To determine the genitourinary (GU) toxicity outcomes in prostate cancerpatients treated with stereotactic body radiation therapy (SBRT) who have undergone a prior transurethral resection of prostate (TURP) and compare it to a similar non-TURP cohort. MATERIALS AND METHODS: Fifty prostate cancerpatients who had undergone a single TURP, had a good baseline urinary function, and had been subsequently treated with SBRT were chosen from a prospectively maintained database. These were propensity score matched to a similar non-TURP cohort treated during the same period. Matching was done for diabetes mellitus and volume of radiation therapy. Acute GU and late GU toxicity were scored using the Radiation Therapy Oncology Group (RTOG) criteria. Stricture and incontinence were scored using Common Terminology for Common Adverse Events version 4.0. RESULTS: Median follow-up for the entire cohort was 26 months (non-TURP vs TURP, 30 months vs 22 months, P = .34). The median duration between TURP and start of SBRT was 10 months. There was no significant difference between non-TURP versus TURP cohort in terms of RTOG acute GU toxicities grade ≥2 (8% vs 6%, P = .45), RTOG late GU toxicities grade ≥2 (8% vs 12%, P = .10), stricture rates (4% vs 6%, P = .64), and incontinence rates (0% vs 4%, P = .15). The median duration of time to late toxicity was 16 months vs 10 months (P = .12) in non-TURP and TURP cohort, respectively. CONCLUSIONS: Although modestly increased as compared with non-TURP patients, GU toxicities remains low with SBRT in post-TURP patients. SBRT can be safely performed in carefully selected post-TURP prostate cancerpatients.
Authors: Luca F Valle; Dan Ruan; Audrey Dang; Rebecca G Levin-Epstein; Ankur P Patel; Joanne B Weidhaas; Nicholas G Nickols; Percy P Lee; Daniel A Low; X Sharon Qi; Christopher R King; Michael L Steinberg; Patrick A Kupelian; Minsong Cao; Amar U Kishan Journal: Front Oncol Date: 2020-05-20 Impact factor: 6.244
Authors: Abigail Pepin; Nima Aghdam; Sarthak Shah; Shaan Kataria; Harry Tsou; Subhradeep Datta; Malika Danner; Marilyn Ayoob; Thomas Yung; Siyuan Lei; Marie Gurka; Brian T Collins; Pranay Krishnan; Simeng Suy; Ryan Hankins; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2020-05-05 Impact factor: 6.244
Authors: Daniel Gorovets; Margaret Hopkins; Debra A Goldman; Ruth Levy Abitbol; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Michael J Zelefsky Journal: Adv Radiat Oncol Date: 2020-10-12